The Technical Analyst
Summit Therapeutics plc [SMMT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Summit Therapeutics plc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
19.59% $4.70
America/New_York / 1 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3 297.80 mill |
| EPS: | -0.990 |
| P/E: | -4.75 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 701.66 mill |
| Avg Daily Volume: | 2.14 mill |
| RATING 2024-05-01 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.75 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.81x |
| Company: PE -4.75 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0699 (-101.49%) $-4.77 |
| Date: 2024-05-01 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.31 - 5.05 ( +/- 7.91%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-11 | Ronaghi Mostafa | Buy | 25 315 | Stock Option (right to buy) |
| 2024-04-11 | Ronaghi Mostafa | Buy | 200 000 | Stock Option (right to buy) |
| 2024-04-11 | Ronaghi Mostafa | Buy | 0 | |
| 2024-04-02 | Soni Manmeet Singh | Buy | 1 100 000 | Stock Option (right to buy) |
| 2024-04-02 | Anand Bhaskar | Buy | 600 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 99.43 |
| Last 89 transactions |
| Buy: 581 405 260 | Sell: 937 995 |
Forecast:
16:00 - $4.69
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.69
Forecast 2: 16:00 - $4.69
Forecast 3: 16:00 - $4.69
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.70 (19.59% ) |
| Volume | 5.36 mill |
| Avg. Vol. | 2.14 mill |
| % of Avg. Vol | 250.94 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SMMT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $4.15 | N/A | Active |
|---|
SMMT
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Latest Press Releases
2024-05-01 07:00:00 - Press Release
Summit Therapeutics Reports Financial Results And Operational Progress For The First Quarter Ended March 31, 2024
Miami--(business wire)---- $smmt--summit therapeutics inc. (nasdaq: smmt) ("summit," "we," or the "company") today reports its financial results and provides an update on its operational progress for the first quarter ended march 31, 2024. operational & corporate updates our operational progress continues with ivonescimab (smt112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of pd-1 with the anti-angiogenesis effects associa.
2024-04-24 16:30:00 - Press Release
Summit Therapeutics To Host First Quarter 2024 Financial Results & Operational Progress Call On May 1, 2024
Miami--(business wire)---- $smmt--summit therapeutics inc. (nasdaq: smmt) (“summit,” “we,” or the “company”) will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the company on wednesday, may 1, 2024, before the market opens. summit will host a live webcast of the earnings conference call at 9:00am et, which will be accessible through our website www.smmttx.com. an archived edition of the session will be available on our website. about ivon.
2024-04-11 16:30:00 - Press Release
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive And Genomicist, To Its Board Of Directors
Miami--(business wire)---- $smmt--summit therapeutics inc. (nasdaq: smmt) (“summit,” “we,” or the “company”) today announced that mostafa ronaghi, phd, has been appointed to its board of directors, effective immediately. “we are excited to add dr. ronaghi to complement our excellent group of current board members,” stated robert w. duggan, chairman and chief executive officer of summit. “mostafa has valuable experience in translating innovative concepts in genomics and sequencing that ultimately lead to.
2024-04-10 07:00:00 - Press Release
Summit Therapeutics To Present At The Stifel 2024 Targeted Oncology Forum
Miami--(business wire)---- $smmt--summit therapeutics inc. (nasdaq: smmt) (“summit,” “we,” or the “company”) today announced that it will participate in and present at the stifel 2024 targeted oncology forum, which will be held virtually april 16-17, 2024. dr. maky zanganeh, chief executive officer and president, robert w. duggan, chairman and chief executive officer, manmeet soni, chief operating officer & chief financial officer, dave gancarz, chief business & strategy officer, and dr. allen s.
2024-04-09 16:05:00 - Press Release
Illumina Appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy And Corporate Development Officer
Joydeep goswami to serve as advisor through june 30 illumina reaffirms q1 2024 and full-year 2024 financial guidance san diego , april 9, 2024 /prnewswire/ -- illumina, inc. (nasdaq: ilmn), a global leader in dna sequencing and array-based technologies, today announced that joydeep goswami has decided to leave illumina. he will stay on in an advisory role through june 30 to support two new executive management team appointments.
Latest News
2024-04-24 16:30:00 - Business Wire
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens. Summit will host a live webcast of the earnings conference call at 9:00am ET, which will be accessible through our website www.smmttx.com. An archived edition of the session will be available on our website. About Ivon.
2024-04-09 16:33:00 - Reuters
Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor
Illumina said on Tuesday Chief Financial Officer Joydeep Goswami would leave the gene sequencing company and would be succeeded by former Summit Therapeutics' executive Ankur Dhingra.
2024-03-29 17:43:13 - The Motley Fool
Why Summit Therapeutics Stock Crushed the Market This Week
An analyst initiated coverage of Summit Therapeutics with an enthusiastic buy recommendation. He feels its investigational cancer drug has vast potential.
2024-03-05 07:00:00 - Business Wire
Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Barclays 26th Annual Global Healthcare Conference, which will be held in Miami Beach, FL, from March 12-14, 2024. Dr. Maky Zanganeh, Chief Executive Officer and President, and Robert W. Duggan, Chairman and Chief Executive Officer, will present on behalf of our organization and provide details regarding the development of our innovativ.
2024-02-20 13:54:13 - Seeking Alpha
Summit Therapeutics Inc. (SMMT) Q4 2023 Earnings Call Transcript
2024-02-14 10:29:00 - Business Wire
Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024
MIAMI, Fla.--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2023 financial results and provide an operational update for the Company on Tuesday, February 20, 2024, before the market opens. Summit will host a live webcast of the earnings conference call at 9:00am ET, which will be accessible through our website www.smmttx.com. An archived edition of the session will be available o.
2023-09-26 15:00:31 - Seeking Alpha
Summit Therapeutics: Not For Retail Investors
Summit Therapeutics Inc., backed by biotech billionaire Bob Duggan, has transitioned from developing antibiotics to becoming an oncology therapeutics developer. The company purchased the oncology asset Ivonescimab for nearly half a billion dollars and now has a market cap of over $1 billion. Summit plans to begin phase 3 trials for Ivonescimab in the U.S., but the Chinese clinical data may not hold much value.
2023-05-16 13:21:13 - The Motley Fool
Why Shares of Summit Therapeutics Slumped on Tuesday
2023-05-05 17:08:50 - The Motley Fool
Why Shares of Summit Therapeutics Soared This Week
The company's current pipeline only includes two drugs. Summit Therapeutics' shares are up more than 93% over the past 12 months.
2023-04-26 00:15:28 - Seeking Alpha
Strong Small-Cap Insider Buys: Q1 2023
